Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention

  Hepatitis

  Free Subscription


13.03.2023

1 Am J Gastroenterol
1 Clin Infect Dis
1 Int J Cancer
2 J Hepatol
1 J Immunol
2 J Infect Dis
5 J Med Virol
1 J Rheumatol
4 J Viral Hepat
1 J Virol
3 JAMA
1 MMWR Recomm Rep
1 PLoS One
1 Proc Natl Acad Sci U S A
2 Vaccine


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Gastroenterol

  1. HUR MH, Park MK, Cheuk-Fung Yip T, Chen CH, et al
    Personalized Antiviral Drug Selection in Chronic Hepatitis B Patients Using a Machine Learning Model: A Multinational Study.
    Am J Gastroenterol. 2023 Mar 7. doi: 10.14309/ajg.0000000000002234.
    PubMed         Abstract available


    Clin Infect Dis

  2. BEISER ME, Shaw LC, Shores SK, Carson JM, et al
    Hepatitis C virus reinfection in a real-world cohort of homeless-experienced individuals in Boston.
    Clin Infect Dis. 2023 Mar 4:ciad127. doi: 10.1093.
    PubMed         Abstract available


    Int J Cancer

  3. PETRICK JL, Florio AA, Zen J, Wang Y, et al
    Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the REVEAL-HBV and REVEAL-HCV Cohort Studies.
    Int J Cancer. 2023 Mar 6. doi: 10.1002/ijc.34492.
    PubMed         Abstract available


    J Hepatol

  4. MONTALI I, Berti CC, Morselli M, Acerbi G, et al
    Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B.
    J Hepatol. 2023 Mar 7:S0168-8278(23)00167-8. doi: 10.1016/j.jhep.2023.
    PubMed         Abstract available

  5. RICCIUTO A, Kamath BM, Hirschfield GM, Trivedi PJ, et al
    Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?
    J Hepatol. 2023 Mar 2:S0168-8278(23)00162-9. doi: 10.1016/j.jhep.2023.
    PubMed         Abstract available


    J Immunol

  6. SUBRAMANIAN K, Paul S, Libby A, Patterson J, et al
    HERV1-env Induces Unfolded Protein Response Activation in Autoimmune Liver Disease: A Potential Mechanism for Regulatory T Cell Dysfunction.
    J Immunol. 2023 Feb 1:ji2100186. doi: 10.4049/jimmunol.2100186.
    PubMed         Abstract available


    J Infect Dis

  7. LIND ML, Copin R, McCarthy S, Coppi A, et al
    Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness.
    J Infect Dis. 2022 Nov 21:jiac453. doi: 10.1093.
    PubMed         Abstract available

  8. SUEHIRO Y, Tsuge M, Kurihara M, Uchida T, et al
    Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL.
    J Infect Dis. 2023;227:686-695.
    PubMed         Abstract available


    J Med Virol

  9. LIU Y, Chen M
    Is nonalcoholic fatty liver disease a predictor of treatment response in chronic hepatitis B?
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28654.
    PubMed         Abstract available

  10. XU W, Zhu S, Yang L, Li Z, et al
    Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28650.
    PubMed         Abstract available

  11. FENG Z, Huang P, Zhang J, Xia X, et al
    KIR2DL4/HLA-G polymorphisms were associated with HCV infection susceptibility among Chinese high-risk population.
    J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28645.
    PubMed         Abstract available

  12. CHARRE C, Regue H, Deny P, Josset L, et al
    Improved Hepatitis Delta Virus genome characterization by single molecule full-length genome sequencing combined with VIRiONT pipeline.
    J Med Virol. 2023 Mar 6. doi: 10.1002/jmv.28634.
    PubMed         Abstract available

  13. CAI T, Yue T, Xu M, Zhang P, et al
    Poor glycemic control in type-2 diabetic patients infected with hepatitis B: a retrospective propensity-matched study.
    J Med Virol. 2023 Mar 4. doi: 10.1002/jmv.28635.
    PubMed         Abstract available


    J Rheumatol

  14. ALJABERI N, Ghulam E, Smitherman EA, Favier L, et al
    Maintaining Hepatitis B Protection in Immunocompromised Pediatric Rheumatology and Inflammatory Bowel Disease Patients.
    J Rheumatol. 2021;48:1314-1321.
    PubMed         Abstract available


    J Viral Hepat

  15. MOONEYHAN E, De la Torre Rosas A, Serrano DB, Gamkrelidze I, et al
    Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico.
    J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13828.
    PubMed         Abstract available

  16. QIU L, Xu S, Qiu Y, Liu Y, et al
    Comparison of acknowledged hepatocellular carcinoma risk scores in high risk hepatitis C patients with sustained virologic response.
    J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13829.
    PubMed         Abstract available

  17. MOREAU C, Roux M, Riou J, Canivet CM, et al
    Dynamic Personalized Prediction of the Individual Liver-Related Risk after Sustained Viral Response in HCV patients.
    J Viral Hepat. 2023 Mar 9. doi: 10.1111/jvh.13830.
    PubMed         Abstract available

  18. SELIM R, Zhou Y, Gordon SC, Zhang T, et al
    Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals.
    J Viral Hepat. 2023 Mar 5. doi: 10.1111/jvh.13826.
    PubMed         Abstract available


    J Virol

  19. ZAIETS I, Gunewardena S, Menne S, Weinman SA, et al
    Sera of Individuals Chronically Infected with Hepatitis B Virus (HBV) Contain Diverse RNA Types Produced by HBV Replication or Derived from Integrated HBV DNA.
    J Virol. 2023 Mar 6:e0195022. doi: 10.1128/jvi.01950.
    PubMed         Abstract available


    JAMA

  20. ABBASI J
    Former NIH Director Francis S. Collins on the New White House Plan to Eliminate Hepatitis C.
    JAMA. 2023 Mar 9. doi: 10.1001/jama.2023.3942.
    PubMed        

  21. FLEURENCE RL, Collins FS
    A National Hepatitis C Elimination Program in the United States: A Historic Opportunity.
    JAMA. 2023 Mar 9. doi: 10.1001/jama.2023.3692.
    PubMed        

  22. SO S, Terrault N, Conners EE
    Universal Adult Hepatitis B Screening and Vaccination as the Path to Elimination.
    JAMA. 2023 Mar 10. doi: 10.1001/jama.2023.2806.
    PubMed        


    MMWR Recomm Rep

  23. CONNERS EE, Panagiotakopoulos L, Hofmeister MG, Spradling PR, et al
    Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023.
    MMWR Recomm Rep. 2023;72:1-25.
    PubMed         Abstract available


    PLoS One

  24. SCHMIDBAUER C, Schwarz M, Schutz A, Schubert R, et al
    Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
    PLoS One. 2021;16:e0252274.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  25. RASCHE A, Lehmann F, Goldmann N, Nagel M, et al
    A hepatitis B virus causes chronic infections in equids worldwide.
    Proc Natl Acad Sci U S A. 2021;118:e2013982118.
    PubMed         Abstract available


    Vaccine

  26. KNUF M, Haas H, Garcia-Corbeira P, Turriani E, et al
    Hexavalent vaccines: What can we learn from head-to-head studies?
    Vaccine. 2021;39:6025-6036.
    PubMed         Abstract available

  27. WU L, Yang S, Huang Z, Liu J, et al
    Safety of concomitant administration of inactivated hepatitis A vaccine with other vaccines in children under 16 years old in post-marketing surveillance.
    Vaccine. 2023 Mar 3:S0264-410X(23)00226-8. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: